peplexicon

A living atlas of therapeutic peptides

See the signal.
Follow the evidence.

An expanding library of source-linked profiles connected by mechanism, anatomy, clinical use, and safety.

Mapping peptide relationships…
GLP-1 receptor agonistSemaglutide

A long-acting GLP-1 analog with product-specific indications spanning type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.

Drag to orbit · Select a peptide to enter
01Peptide universeEdition 01 · expanding atlas

The lexicon

Not a list of promises.
A map of what is known.

Peplexicon separates ingredient from product ↗, mechanism from outcome, and reviewed evidence from the unfiltered research universe.

Every profile shows consumer-facing brand names beside the official ingredient, then anchors claims and safety language to inspectable sources ↗.

Edition 01 · Therapeutic peptides

Peptide profiles,
fully traced.

Approved ingredients first, with a structure designed to expand into investigational compounds and new evidence classes.

  1. 01
    SemaglutideOzempic · Wegovy · Rybelsus
    GLP-1 receptor agonist
  2. 02
    TirzepatideMounjaro · Zepbound
    Dual GIP/GLP-1 receptor agonist
  3. 03
    LiraglutideVictoza · Saxenda
    GLP-1 receptor agonist
  4. 04
    ExenatideByetta · Bydureon BCise
    GLP-1 receptor agonist
  5. 05
    PramlintideSymlinPen
    Amylin analog
  6. 06
    TesamorelinEgrifta WR · Egrifta SV
    Growth hormone–releasing factor analog
  7. 07
    OctreotideSandostatin · Sandostatin LAR Depot · Mycapssa
    Somatostatin analog
  8. 08
    LeuprolideLupron Depot · Eligard · Fensolvi · Camcevi
    Gonadotropin-releasing hormone agonist
  9. 09
    TeriparatideForteo · Bonsity · Teriparatide injection
    Parathyroid hormone analog
  10. 10
    DesmopressinDDAVP · Nocdurna
    Vasopressin analog

How to read Peplexicon

01

Brand is not identity.

Consumer names are products with distinct routes, strengths, indications, and instructions.

See an example ↗02

A signal is not a conclusion.

Mechanism, randomized outcomes, labels, and spontaneous reports answer different questions.

Read the evidence ↗03

The source stays visible.

Claims link outward so readers can inspect the population, comparator, endpoint, and limitations.

Open the sources ↗